Rac1 is required for Prkar1a-mediated Nf2 suppression in Schwann cell tumors

Oncogene

Volumn 32, Issue 30, 2013, Pages 3491-3499

  Manchanda, P K ^a   Jones, G N ^a,b   Lee, A A ^a   Pringle, D R ^a   Zhang, M ^a   Yu, L ^a   La Perle, K M D ^a   Kirschner, L S ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Merlin; PKA; PRKAR1A; Rac1; Schwann cell tumor

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; MERLIN; PRKAR1A PROTEIN; RAC1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CARNEY COMPLEX; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; GENE ACTIVATION; GENE LOSS; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; NEURILEMOMA; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT; SCHWANN CELL; SIGNAL TRANSDUCTION; TUMOR PROMOTION;

ANIMALS; CYCLIC AMP-DEPENDENT PROTEIN KINASE RIALPHA SUBUNIT; DOWN-REGULATION; GENES, NEUROFIBROMATOSIS 2; MICE; MICE, KNOCKOUT; NEURILEMMOMA; NEUROPEPTIDES; RAC GTP-BINDING PROTEINS; RAC1 GTP-BINDING PROTEIN; SCHWANN CELLS;

EID: 84880917461     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.374     Document Type: Article

References (50)

1. Kissil JL, Blakeley JO, Ferner RE, Huson SM, Kalamarides M, Mautner VF et al. What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers. Am J Med Genet A 2010; 152A: 269-283.
2. Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P. Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet 2007; 80: 805-810. (Pubitemid 46564417)
3. Kirschner LS, Sandrini F, Monbo J, Lin JP, Carney JA, Stratakis CA. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the carney complex. Hum Mol Genet 2000; 9: 3037-3046. (Pubitemid 32000777)
4. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 2000; 26: 89-92.
5. Kim HA, DeClue JE, Ratner N. cAMP-dependent protein kinase A is required for Schwann cell growth: interactions between the cAMP and neuregulin/tyrosine kinase pathways. J Neurosci Res 1997; 49: 236-247. (Pubitemid 27332722)
6. Howe DG, McCarthy KD. Retroviral inhibition of cAMP-dependent protein kinase inhibits myelination but not Schwann cell mitosis stimulated by interaction with neurons. J Neurosci 2000; 20: 3513-3521. (Pubitemid 30266212)
7. Izawa I, Tamaki N, Saya H. Phosphorylation of neurofibromatosis type 1 gene product (neurofibromin) by cAMP-dependent protein kinase. FEBS Lett 1996; 382: 53-59. (Pubitemid 26092233)
8. Alfthan K, Heiska L, Gronholm M, Renkema GH, Carpen O. Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 518 independently of p21-activated kinase and promotes merlin-ezrin heterodimerization. J Biol Chem 2004; 279: 18559-18566. (Pubitemid 38623276)
9. Laulajainen M, Muranen T, Carpen O, Gronholm M. Protein kinase A-mediated phosphorylation of the NF2 tumor suppressor protein merlin at serine 10 affects the actin cytoskeleton. Oncogene 2008; 27: 3233-3243. (Pubitemid 351733388)
10. Kissil JL, Johnson KC, Eckman MS, Jacks T. Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem 2002; 277: 10394-10399. (Pubitemid 34968159)
11. Xiao GH, Beeser A, Chernoff J, Testa JR. p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem 2002; 277: 883-886. (Pubitemid 34968830)
12. Thaxton C, Lopera J, Bott M, Baldwin ME, Kalidas P, Fernandez-Valle C. Phosphorylation of the NF2 tumor suppressor in Schwann cells is mediated by Cdc42-Pak and requires paxillin binding. Mol Cell Neurosci 2007; 34: 231-242. (Pubitemid 46136999)
13. Kim HA, Ratner N, Roberts TM, Stiles CD. Schwann cell proliferative responses to cAMP and Nf1 are mediated by cyclin D1. J Neurosci 2001; 21: 1110-1116. (Pubitemid 32128756)
14. Tonks ID, Nurcombe V, Paterson C, Zournazi A, Prather C, Mould AW et al. Tyrosinase-Cre mice for tissue-specific gene ablation in neural crest and neuroepithelial-derived tissues. Genesis 2003; 37: 131-138. (Pubitemid 37486874)
15. Jones GN, Tep C, Towns 2nd WH, Mihai G, Tonks ID, Kay GF et al. Tissue-specific ablation of Prkar1a causes schwannomas by suppressing neurofibromatosis protein production. Neoplasia 2008; 10: 1213-1221.
16. Jones GN, Pringle DR, Yin Z, Carlton MM, Powell KA, Weinstein MB et al. Neural crest-specific loss of Prkar1a causes perinatal lethality resulting from defects in intramembranous ossification. Mol Endocrinol 2010; 24: 1559-1568.
17. Okada T, You L, Giancotti FG. Shedding light on Merlin's wizardry. Trends Cell Biol 2007; 17: 222-229. (Pubitemid 46679247)
18. Yin Z, Williams-Simons L, Rawahneh L, Asa S, Kirschner LS. Development of a pituitary-specific cre line targeted to the Pit-1 lineage. Genesis 2008; 46: 37-42. (Pubitemid 351413586)
19. Stemmer-Rachamimov AO, Louis DN, Nielsen GP, Antonescu CR, Borowsky AD, Bronson RT et al. Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res 2004; 64: 3718-3724. (Pubitemid 38657953)
20. Kirschner LS, Kusewitt DF, Matyakhina L, Towns 2nd WH, Carney JA, Westphal H et al. A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. Cancer Res 2005; 65: 4506-4514. (Pubitemid 40740784)
21. Sainz J, Huynh DP, Figueroa K, Ragge NK, Baser ME, Pulst SM. Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. Hum Mol Genet 1994; 3: 885-891. (Pubitemid 24189953)
22. Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I et al. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell 2001; 1: 63-72. (Pubitemid 33586069)
23. Beeser A, Jaffer ZM, Hofmann C, Chernoff J. Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors. J Biol Chem 2005; 280: 36609-36615. (Pubitemid 41587737)
24. Bashour AM, Meng JJ, Ip W, MacCollin M, Ratner N. The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells. Mol Cell Biol 2002; 22: 1150-1157. (Pubitemid 34094851)
25. Pelton PD, Sherman LS, Rizvi TA, Marchionni MA, Wood P, Friedman RA et al. Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells. Oncogene 1998; 17: 2195-2209. (Pubitemid 28515373)
26. Cotteret S, Chernoff J. The evolutionary history of effectors downstream of Cdc42 and Rac. Genome Biol 2002; 3: REVIEWS0002.
27. Pankov R, Endo Y, Even-Ram S, Araki M, Clark K, Cukierman E et al. A Rac switch regulates random versus directionally persistent cell migration. J Cell Biol 2005; 170: 793-802. (Pubitemid 41242111)
28. Flaiz C, Chernoff J, Ammoun S, Peterson JR, Hanemann CO. PAK kinase regulates Rac GT Pase and is a potential target in human schwannomas. Exp Neurol 2009; 218: 137-144.
29. Thurnherr T, Benninger Y, Wu X, Chrostek A, Krause SM, Nave KA et al. Cdc42 and Rac1 signaling are both required for and act synergistically in the correct formation of myelin sheaths in the CNS. J Neurosci 2006; 26: 10110-10119. (Pubitemid 44527405)
30. Feltri ML, Suter U, Relvas JB. The function of Rho GT Pases in axon ensheathment and myelination. Glia 2008; 56: 1508-1517.
31. Chan JR. Myelination: all about Rac 'n' roll. J Cell Biol 2007; 177: 953-955. (Pubitemid 46955700)
32. Krause S, Stendel C, Senderek J, Relvas JB, Suter U. Small Rho GT Pases are key regulators of peripheral nerve biology in health and disease. J Peripher Nerv Syst 2008; 13: 188-199.
33. Benninger Y, Thurnherr T, Pereira JA, Krause S, Wu X, Chrostek-Grashoff A et al. Essential and distinct roles for cdc42 and rac1 in the regulation of Schwann cell biology during peripheral nervous system development. J Cell Biol 2007; 177: 1051-1061. (Pubitemid 46955709)
34. Lang P, Gesbert F, Delespine-Carmagnat M, Stancou R, Pouchelet M, Bertoglio J. Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. Embo J 1996; 15: 510-519. (Pubitemid 26044564)
35. O'Connor KL, Mercurio AM. Protein kinase A regulates Rac and is required for the growth factor-stimulated migration of carcinoma cells. J Biol Chem 2001; 276: 47895-47900.
36. Okada T, Lopez-Lago M, Giancotti FG. Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol 2005; 171: 361-371. (Pubitemid 41540027)
37. Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, Jacks T. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell 2003; 12: 841-849. (Pubitemid 37352778)
38. Kaempchen K, Mielke K, Utermark T, Langmesser S, Hanemann CO. Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Hum Mol Genet 2003; 12: 1211-1221. (Pubitemid 36722601)
39. Thaxton C, Lopera J, Bott M, Fernandez-Valle C. Neuregulin and laminin stimulate phosphorylation of the NF2 tumor suppressor in Schwann cells by distinct protein kinase A and p21-activated kinase-dependent pathways. Oncogene 2008; 27: 2705-2715. (Pubitemid 351581460)
40. Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 2001; 15: 968-980. (Pubitemid 32323547)
41. Xiao GH, Gallagher R, Shetler J, Skele K, Altomare DA, Pestell RG et al. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol 2005; 25: 2384-2394. (Pubitemid 40354632)
42. Schulze KM, Hanemann CO, Muller HW, Hanenberg H. Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis. Hum Mol Genet 2002; 11: 69-76. (Pubitemid 34100769)
43. Herrlich P, Morrison H, Sleeman J, Orian-Rousseau V, Konig H, Weg-Remers S et al. CD44 acts both as a growth-and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann N Y Acad Sci 2000; 910: 106-118; discussion 18-20.
44. Gautreau A, Manent J, Fievet B, Louvard D, Giovannini M, Arpin M. Mutant products of the NF2 tumor suppressor gene are degraded by the ubiquitin-proteasome pathway. J Biol Chem 2002; 277: 31279-31282. (Pubitemid 34968924)
45. Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T. The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem 2007; 282: 8256-8264. (Pubitemid 47093612)
46. Zhang M, Siedow M, Saia G, Chakravarti A. Inhibition of p21-activated kinase 6 (PAK6) increases radiosensitivity of prostate cancer cells. Prostate 2010; 70: 807-816.
47. Glogauer M, Marchal CC, Zhu F, Worku A, Clausen BE, Foerster I et al. Rac1 deletion in mouse neutrophils has selective effects on neutrophil functions. J Immunol 2003; 170: 5652-5657. (Pubitemid 36617857)
48. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 1999; 21: 70-71. (Pubitemid 29036285)
49. Crabtree JS, Scacheri PC, Ward JM, McNally SR, Swain GP, Montagna C et al. Of mice and MEN1: Insulinomas in a conditional mouse knockout. Mol Cell Biol 2003; 23: 6075-6085. (Pubitemid 37013087)
50. Brockes JP, Fields KL, Raff MC. Studies on cultured rat Schwann cells. I. Establishment of purified populations from cultures of peripheral nerve. Brain Res 1979; 165: 105-118. (Pubitemid 9148699)